Your AI-Trained Oncology Knowledge Connection!

Susan O'Brien, MD

home / authors / susan-o-brien-md

Articles

Unmet Needs and Future Perspectives in the Treatment of CLL

Susan O'Brien, MD;Alexey Danilov, MD, PhD;Seema Ali Bhat, MD;Catherine Coombs, MD

February 24th 2023

The panel shares some final thoughts on unmet needs and the future of CLL treatment.

Emerging Therapies in CLL

Susan O'Brien, MD;Alexey Danilov, MD, PhD;Seema Ali Bhat, MD;Catherine Coombs, MD

February 24th 2023

Dr Alexey Danilov explains data on emerging therapies, including anti-ROR1 therapies, BTK degrading agents, and bispecifics, for treatment of CLL.

Sequencing Therapies in CLL

Susan O'Brien, MD;Alexey Danilov, MD, PhD;Seema Ali Bhat, MD;Catherine Coombs, MD

February 24th 2023

The panel shares their thoughts on sequencing the available therapies in patients with CLL.

Role of Venetoclax in Patients with High-Risk CLL

Susan O'Brien, MD;Alexey Danilov, MD, PhD;Seema Ali Bhat, MD;Catherine Coombs, MD

February 10th 2023

Dr Catherine Coombs explains the challenges of treating 17p deletions and Richter’s syndrome in patients with CLL and discusses the role of venetoclax in the treatment of these patients.

Fixed-Duration Venetoclax in the Treatment of CLL

Susan O'Brien, MD;Alexey Danilov, MD, PhD;Seema Ali Bhat, MD;Catherine Coombs, MD

February 10th 2023

Seema Ali Bhat, MD, and Alexey Danilov, MD, PhD, discuss data updates on the use of fixed-duration venetoclax for the treatment of CLL.

Non-Covalent BTK Inhibitors in the Treatment of CLL: Nemtabrutinib

Susan O'Brien, MD;Alexey Danilov, MD, PhD;Seema Ali Bhat, MD;Catherine Coombs, MD

February 3rd 2023

Dr Seema Ali Bhat continues the conversation on non-covalent BTK inhibitors in CLL treatment with a look at nemtabrutinib and data from the BELLWAVE-001 study.

Non-Covalent BTK Inhibitors in the Treatment of CLL: Pirtobrutinib

Susan O'Brien, MD;Alexey Danilov, MD, PhD;Seema Ali Bhat, MD;Catherine Coombs, MD

February 3rd 2023

Catherine Coombs, MD, and Alexey Danilov, MD, PhD, discuss data on the investigational non-covalent BTK inhibitor pirtobrutinib for the treatment of CLL.

Selecting an Appropriate BTK Inhibitor for the Treatment of Relapsed CLL

Susan O'Brien, MD;Alexey Danilov, MD, PhD;Seema Ali Bhat, MD;Catherine Coombs, MD

January 27th 2023

The panel explains the factors they consider when deciding on a BTK inhibitor for the treatment of patients with CLL.

Comparing BTK Inhibitors in the Treatment of Relapsed CLL

Susan O'Brien, MD;Alexey Danilov, MD, PhD;Seema Ali Bhat, MD;Catherine Coombs, MD

January 27th 2023

Drs Susan O’Brien and Catherine Coombs describe the design and outcomes of the ELEVATE-RR and ALPINE trials that compare BTK inhibitors in CLL.

BTK Inhibitors for the Treatment of Relapsed CLL

Susan O'Brien, MD;Alexey Danilov, MD, PhD;Seema Ali Bhat, MD;Catherine Coombs, MD

January 20th 2023

Seema Ali Bhat, MD, explains the SEQUOIA trial and the BTK inhibitor zanubrutinib for the frontline treatment of CLL, and Alexey Danilov, MD, PhD, describes the ASCEND trial that led to the approval of acalabrutinib for relapsed CLL.

Selecting the Appropriate BTK Inhibitor for Frontline Treatment of CLL

Susan O'Brien, MD;Alexey Danilov, MD, PhD;Seema Ali Bhat, MD;Catherine Coombs, MD

January 20th 2023

Catherine Coombs, MD, reviews data on BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in the first-line treatment of CLL, and how she approaches selecting the appropriate BTK inhibitor in practice.

Mechanism of Action of BTK Inhibitors in Chronic Lymphocytic Leukemia

Susan O'Brien, MD;Alexey Danilov, MD, PhD;Seema Ali Bhat, MD;Catherine Coombs, MD

December 20th 2022

Susan O’Brien, MD, provides a brief overview of chronic lymphocytic leukemia (CLL), and Seema Ali Bhat, MD, explains the mechanism of BTK inhibitors.